The upfront ratio is the deal. $125 million certain against a disclosed maximum of $2,093 million puts roughly 6% of the money on the table at signing, and that is a striking number for an asset already in Phase III. Structure follows conviction, so read it plainly: Alphamab is financing Pathos’ option. If JSKN016 works outside China, Alphamab is paid handsomely and late. If it does not, Alphamab keeps the $125 million and Pathos absorbs a global development programme it has agreed to fund in full. Six percent down on a registrational-stage asset says either the ex-China auction was thin or the buyer could not write a larger cheque. Both are worth knowing.

• What Alphamab kept is more informative than what it sold. It retained Greater China outright, which is exactly where its own commercial infrastructure and its ongoing Phase III already sit, and sold the territories it has no way to serve. That is the mature form of the China out-licensing model: keep the market you can reach, sell the one you cannot, and take payment in optionality rather than cash. With six bispecific and dual-payload ADCs in the clinic and prior deals with CSPC, ArriVent and Glenmark, this is a repeat process rather than an opportunistic sale, and the terms should be read as a house standard rather than a one-off valuation.
• Competitive frame: JSKN016 enters the most contested target in oncology from an unusual angle. Adding HER3 to a TROP2 backbone is a bet that dual targeting answers the heterogeneity and resistance problems that single-target TROP2 programmes have run into, and a DAR of 4 with site-specific glycosylation points at a therapeutic-window argument rather than a potency one. The number to demand is the TNBC Phase III readout with comparator context. Watch the subcutaneous formulation just as closely, because subcutaneous delivery is Alphamab’s demonstrated capability and in a class defined by infusion burden it is a more durable differentiator than another point of response rate.
• What to watch: Pathos is private and has now assembled a four-asset clinical pipeline entirely through in-licensing and acquisition, with every release crediting Foundry for the selection. The asset is the product demonstration, which is coherent, and it also means the pipeline’s value and the platform’s credibility have become the same thing. The day after this agreement Pathos announced a co-exclusive collaboration with AstraZeneca on AZD4241. A company stacking proof points at that pace usually has a financing behind it. Watch for the raise, and watch whether Pathos ever publishes a registrational path for JSKN016 outside China, because it has committed to pay for all of it.